^
    Back
    Association details:
    Biomarker:KIT A829P
    Cancer:Melanoma
    Drug:imatinib (c-KIT inhibitor, Bcr-abl inhibitor, PDGFR inhibitor)
    Direction:Resistant
    Evidence:
    Evidence Level:
    Resistant: C3 – Early Trials
    New
    Source:
    Pigment Cell Melanoma Res
    Title:

    Secondary c-Kit mutations confer acquired resistance to RTK inhibitors in c-Kit mutant melanoma cells

    Excerpt:
    The secondary A829P c-Kit mutation rendered cells resistant to imatinib, but did not suppress the activity of the tyrosine kinase inhibitors nilotinib and dasatinib.
    DOI:
    10.1111/pcmr.12107